Publications by authors named "Tetsu Hirakawa"
Introduction: Docetaxel plus ramucirumab (DTX + RAM) therapy is a standard treatment for previously treated lung cancer, but many adverse events have been reported. This retrospective study was conducted to examine if the side effects of DTX + RAM therapy can be minimized by the combined use of oral dexamethasone (DEX), and to assess the therapeutic effect of DTX + RAM in patients with recurrent lung cancer.
Methods: Forty patients with relapsed non-small cell lung cancer who underwent DTX + RAM therapy were divided into two groups based on the concomitant use of oral DEX, and the therapeutic effects and toxicities in the two groups were compared.
Article Synopsis
- The study examined the effectiveness of comprehensive genomic profiling (CGP) in Japanese patients with thoracic cancers after they completed standard treatments, revealing its potential value in clinical practice.
- Out of 56 patients, 84% had actionable genetic alterations, but only 14% received therapies that matched their genetic profiles.
- The CGP panel was able to identify additional genetic alterations in some patients who had previously undergone multiplex gene-panel testing, suggesting it could help in finding suitable treatments for those who might not have been detected otherwise.
A 50-year-old woman presented with left pleural effusion. A pleural fluid cell-block specimen and longitudinal lymph node needle biopsy suggested signet ring cell carcinoma (SRCC). Although computed tomography showed a consolidation shadow in the left lower lobe, a left lung biopsy could not be performed.
View Article and Find Full Text PDFBackground: Pegfilgrastim is recommended in docetaxel plus ramucirumab (DTX + RAM) therapy for recurrent nonsmall cell lung cancer (NSCLC) because of the associated frequency of febrile neutropenia (FN). However, the FN occurs less frequently when the dose of DTX is reduced because of other adverse events, such as appetite loss and oral mucositis.
Methods And Results: Twenty-two patients with recurrent NSCLC who received DTX + RAM therapy at the Hiroshima Prefectural Hospital.
To the best of our knowledge, systemic sclerosis with overlapping characteristics of both microscopic polyangiitis and giant cell arteritis (i.e. microscopic polyangiitis involving the superficial temporal artery or giant cell arteritis with myeloperoxidase anti-neutrophil cytoplasmic antibody seropositivity) has not been reported previously.
View Article and Find Full Text PDFArticle Synopsis
- This study assessed how effective baricitinib is for treating COVID-19 in patients with respiratory failure, using a cohort of 404 hospitalized adults between late 2020 and mid-2021.
- Among the 229 patients with respiratory failure, 41 were treated with baricitinib and 41 served as a control group, matched for comparison.
- The results showed that the 30-day survival rate was significantly better for those treated with baricitinib, although there was no notable difference in survival rates at 60 days, indicating a need for further improvements in long-term outcomes.
Aim: This study aimed to investigate useful prognostic factors of immunotherapy in patients with lung cancer.
Patients And Methods: We retrospectively observed 73 patients who underwent immunotherapy (nivolumab, pembrolizumab, and atezolizumab) for lung cancer. The systemic inflammatory score (SIS) was calculated as the sum of the following factors scored one point each: Hemoglobin <12.